Chahal D, Sidhu H, Zhao B, et al. - Researchers aimed at retrieving data regarding the use pattern of hemospray (TC-325) in gastrointestinal bleeding. In addition , they investigated their efficacy, complications, and impact on clinical outcomes. Electronic search from relevant databases yielded 27 articles for inclusion in this analysis (n = 1,916). Findings revealed pooled hemostasis in 94.5%; pooled rebleed rate of 9.9% within 3 days, and 17.6% within 30 days. Pooled repeat Hemospray use was reported in 13.6%. Radiology guided embolization was necessitated in 3.3% and surgery at a rate of 4.7%. Overall findings suggest an increased rate of immediate hemostasis in correlation with adding Hemospray to conventional therapy but there was no reduction in rebleeding or mortality. As such, the use of Hemospray will likely be limited to clinical situations necessitating urgent, but temporary, hemostasis to bridge to more definitive therapy.